Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
267
-
Total 13F shares, excl. options
-
96.1M
-
Shares change
-
+12.1M
-
Total reported value, excl. options
-
$1.53B
-
Value change
-
+$192M
-
Put/Call ratio
-
1.66
-
Number of buys
-
154
-
Number of sells
-
-108
-
Price
-
$15.94
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q1 2024
312 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q1 2024.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 267 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 96.1M shares
of 123M outstanding shares and own 78.05% of the company stock.
Largest 10 shareholders include BlackRock Inc. (17.7M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (9.13M shares), STATE STREET CORP (8.15M shares), VANGUARD GROUP INC (7.98M shares), DIMENSIONAL FUND ADVISORS LP (2.74M shares), JANUS HENDERSON GROUP PLC (2.73M shares), GEODE CAPITAL MANAGEMENT, LLC (2.51M shares), ROYCE & ASSOCIATES LP (2.08M shares), RENAISSANCE TECHNOLOGIES LLC (1.89M shares), and MORGAN STANLEY (1.8M shares).
This table shows the top 267 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.